Navigation Links
AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial,with Alkaline Phosphatase in Acute Renal Failure

Results expand potential application of key product in AM-Pharma's pipeline

BUNNIK, The Netherlands, 14 March, 2007. AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, today announced positive results in patients with Acute Renal Failure. The patients involved were a subgroup of a Phase IIa trial with Alkaline Phosphatase to treat Sepsis.

Plasma creatinine clearance, a marker for renal function, improved by 45% (median) in patients with Acute Renal Failure treated with Alkaline Phosphatase and deteriorated by 25% (median) in patients with Acute Renal Failure treated with placebo, with p values of < 0.05.


In addition, the level of glutathione-S-transferase-A1, a marker for kidney damage, decreased by 70% (median) in AP treated patients, compared to a 200% (median) increase in placebo treated patients, with p values again of < 0.05.


Fifteen patients (10 active, 5 placebo) with Acute Renal Failure were treated for 24 hours as part of a double-blind, randomized, placebo-controlled Phase IIa study in 36 Sepsis patients. The study took place in the Department of Intensive Care Medicine at the Radboud University Medical Centre, Nijmegen, The Netherlands.


Bart Wuurman, CEO of AM-Pharma commented on the positive results, saying: "We are very excited by the results in this Acute Renal Failure subgroup. It shows statistically significant and clinically relevant improvements in a condition that is very difficult to treat, has a high mortality rate and is associated with high costs through long term dialysis treatment. We now plan to explore the use of Alkaline Phosphatase in Acute Renal Failure in a separate study."


- ENDS -

Notes to editors:

About AM-Pharma www.am-pharma.com <http://www.am-pharma.com/> AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of novel compounds in the field of severe infectious diseases and inflammatory diseases.

AM-Pharma is currently conducting Phase II clinical trials on two products:

* Alkaline Phosphatase for Sepsis, Acute Renal Failure and Ulcerative Colitis. * Anti-microbial Peptide hLF1-11,for the prevention of infections in Hemopoietic Stem Cell Transplant patients.

AM Pharma is based in Bunnik, The Netherlands with a staff of 20. The company is financed by, amongst others, Forbion Capital Partners and Inventages Venture Capital. Once product safety and efficacy have been established, AM-Pharma will look for world-wide development and marketing partners for its products.

About Acute Renal Failure Hospital-acquired Acute Renal Failure occurs in as many as 4% of hospital admissions and 20% of critical care admissions. The growing incidence of hospital-acquired Acute Renal Failure is due to an increasingly aging population, an increased probability of exposure to nephrotoxic drugs in hospitals and an increasing number of surgical interventions. Depending on the severity of renal failure, mortality rates can range from 7% to as high as 80%. Of patients that do survive, between 20% and 60 % require ongoing dialysis treatment.

*** Should you be interested in downloading a white paper on AM Pharma's Alkaline Phosphatase Phase IIa trial and its application in the treatment of Acute Renal Failure, please click here - www.am-pharma.com <http://www.am-pharma.com/> or contact Justine Lamond on +44 (0)20 7268 3242 or j.lamond@northbankcommunications.com


For further information, please contact

Northbank Communica tions

Justine Lamond

Tel: +44 (0)20 7268 3242

j.lamond@northbankcommunications.com


AM Pharma

CEO Bart Wuurman

Tel: +31 (0)30 2289222

www.am-pharma.com

Justine Lamond Account Manager ---------------------------------------------

Direct line: +44 (0)20 7268 3242 Mobile: +44 (0)7919 828314 Main tel: +44 (0)20 7268 3002 Fax: +44 (0)20 7268 3102

www.northbankcommunications.com

Please note our new address details are:

85 Tottenham Court Road,

London, W1T 4DU UK




'"/>




Related medicine technology :

1. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)...   Click here for supplemental information regarding ... the nation,s largest independent specialty pharmacy, announced today ... acquire Valley Campus Pharmacy, Inc., doing business as ... pharmacy that provides individualized patient care, based in ... 2015, TNH generated approximately $400 million in revenue. ...
(Date:4/28/2016)... BURLINGAME, Calif. , April 28, 2016 /PRNewswire/ ... first-ever widely accessible breast and ovarian cancer risk ... cancer panel analyzing 30 genes that highly impact ... and women. Available today, the Color Test analyzes ... pancreatic, prostate, stomach, and uterine cancers. The Color ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 ... of online consumer insights on healthcare, announced today that ... in their report Cool Vendor in Life Sciences, ... , April 15, 2016.  The report focuses on life-science- ... to gain insight from patients and doctors, confirm medication ...
Breaking Medicine Technology:
(Date:5/3/2016)... , ... May 03, 2016 , ... Elizabeth Murray has ... parrots to join her with one on her shoulder and one on her arm. ... parking lot because of years of mitral valve prolapse. , The valves of the ...
(Date:5/3/2016)... ... ... Excessive panting in the car or cowering when new guests arrive are ... only manifests itself as trembling or ‘tail between the legs,’ but a pet ... about it,” says Dr. Jim Lowe, technical services veterinarian for Tomlyn pet health products ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... been selected by Tidelands Health, a three hospital system in South Carolina, to ... on the lookout for technology that enhances communication, drives workflow efficiencies and improves ...
(Date:5/3/2016)... ... 2016 , ... Boston Children’s Hospital today announced its new pediatric Simulation (SIM) ... or rare procedures in an environment that looks and feels real. , Located in ... inventors and “hackers” to develop and test new devices or software platforms and see ...
(Date:5/3/2016)... OH (PRWEB) , ... May 03, 2016 , ... Each ... a leading cause of death across the United States and account for one death ... and mental impairments or are permanently disabled. HCR ManorCare is launching a video series ...
Breaking Medicine News(10 mins):